A redesigned immune-activating cancer drug has produced striking early results in a small clinical trial, shrinking tumors ...

Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "CD40 Targeted Therapies Clinical Trials, Therapeutic Approaches, Proprietary Technology Platforms & Market Opportunity Insight 2026" report has been ...

Researchers at The University of Texas MD Anderson Cancer Center have characterized the complex microenvironment in angioimmunoblastic T cell lymphoma (AITL), a type of nodal T cell lymphoma, and ...

BOSTON--(BUSINESS WIRE)--Boston Immune Technologies and Therapeutics, Inc. (BITT), a clinical-stage biotechnology company developing novel tumor necrosis factor superfamily receptor (TNFSR) antagonist ...

Apexigen has begun collaborating with Yale Cancer Center on an early-stage clinical trial that combines the biotech’s APX005M CD40 activator with Bristol-Myers Squibb’s Opdivo and cabiralizumab, an ...

Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, ...

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced data from a phase 1 clinical trial combining SEA-CD40 with chemotherapy and an anti-PD-1 in patients with metastatic PDAC at ...

CD4 + T cells expressing CD40 (Th40 cells) constitute a pathogenic T-cell subset that is necessary and sufficient to transfer autoimmune disease. We have previously demonstrated that CD40 signals ...

Boston Immune Technologies and Therapeutics Inc. (BITT) has been awarded funding by the National Institutes of Health (NIH) to support the preclinical development of BITT-101, its CD40 antagonist ...

Efficacy of radioimmunotherapy with (90Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: Results of two phase II trials of the European MCL Network ...